Nevada’s Approach to Unapproved Biological Therapies: What Providers Need to Know
Nevada enacted a law in 2023 legalizing certain non-FDA-approved biological and gene therapies for patients who meet specified criteria, placing it among the early states, alongside Florida and Utah, to build a state framework around therapies the FDA has not approved. The specifics of what that law requires of providers are not cleanly documented in […]
California’s Stem Cell Disclosure Law: What Providers Operating in CA Must Post, Say, and Document
California was the first state in the country to require physicians to disclose the FDA status of stem cell therapy. SB 512, signed in 2017, added Section 684 to the Business and Professions Code and obligates any licensed practitioner who performs a non-FDA-approved stem cell therapy to post a notice, display it at the entrance, […]
IRB Approval vs. Investigational Status: Wyoming SF 48’s Two Pathways for Stem Cell Therapy
Wyoming’s Stem Cell Freedom Act, SF 48, lets a physician perform non-FDA-approved stem cell therapy only if, among other conditions, the therapy is conducted under a current Institutional Review Board approval or the stem cells qualify as an investigational drug, biological product, or device. Those are two distinct legal pathways, and the Act defines each […]
The Wyoming Stem Cell Freedom Act Takes Effect July 1, 2026: What Physicians Need to Know Now
Wyoming’s Stem Cell Freedom Act, Senate File 48, was passed during the 2026 budget session and signed into law. It creates a new article of the Wyoming statutes, W.S. 35-4-1101 through 35-4-1106, and it takes effect July 1, 2026. The Act authorizes physicians to recommend and perform certain non-FDA-approved stem cell therapies and shields a […]
Utah’s Stem Cell Disclosure Law: What Suppliers and Providers Both Must Do Under SB 275
Utah’s stem cell disclosure law lives in Section 58-1-512 of the Utah Code. It began as SB 199 in 2024, which required providers to give patients a written notice and obtain consent before performing non-FDA-approved stem cell therapy. SB 275, passed in the 2025 session, amended that section to add a new obligation aimed upstream […]
Adipose Tissue Banking: 50 Questions Patients Actually Ask, Answered
This page answers the 50 questions patients, physicians, and families most commonly ask about adipose tissue banking, the MFAT procedure, expanded access programs, and the ADSC clinical pipeline, organized by topic so you can go directly to what matters most. Each answer is concise and links to the full post on that topic where you […]
The Adipose-Derived Stem Cell Market in 2026: Science, Pipeline, and What It Means for Patients Who Bank Today
The adipose-derived stem cell market is one of the most active segments in regenerative medicine in 2026, driven by over four hundred active clinical trials, the December 2024 FDA approval of the first MSC-based biologic, and a growing body of published research documenting the multipotent and immunomodulatory properties of ADSCs across orthopedic, autoimmune, neurological, and […]
Is Adipose Tissue Banking Worth the Cost? A Transparent Framework for Evaluating the Investment
Adipose tissue banking costs between $8,000 and $15,000 for the initial package plus annual storage fees, which makes it a significant cash-pay health investment with a return that depends on a pipeline that is maturing but not yet fully realized. Whether it is worth it depends on three things that are entirely specific to you: […]
Why Physicians Are Joining the Save My Fat Provider Network: The Case for Adding Banking to Your Practice
Adipose tissue banking is a service that a growing number of physicians across plastic surgery, aesthetic medicine, orthopedics, and functional medicine are adding to their practices. Not as a departure from their clinical focus, but as a natural extension of it. The harvest technique is within existing physician skill sets, the regulatory framework is established […]
What Happens After You Bank: A Guide to Managing Your Stored Cells and Staying Connected to the Pipeline
Once your viability certificate arrives and your cells are in cryostorage, the active phase of banking is complete, but the value of what you have preserved is just beginning to develop as the ADSC clinical trial pipeline matures toward approvals. The post-banking relationship involves three ongoing responsibilities: maintaining your storage account, staying informed about pipeline […]